FY2025 · ended Dec 31, 2025 · Revenue $2.04M, -67.3% YoY · Filed Mar 9, 2026
Dianthus Therapeutics, Inc. (DNTH) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.0 million and a net loss of $162.3 million. As of Sep 30, 2026 it held $1.2 billion in cash and investments and $1.2 million in total debt.
Revenue
$2.04M
-67.3% vs prior year
Net income
$-162.34M
-91.1% vs prior year
Operating cash flow (TTM)
$-175.15M
-59.9% vs year-ago TTM
Free cash flow
$-29.38M
+51.7% vs prior year
EPS
$-4.20
-64.7% vs prior year
Dividend per share (TTM)
$0.00
Shares outstanding
44.47M
+38.4% vs prior year
Net cash
$1.24B
as of Sep 30, 2026
Operating margin
-8739.3%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DNTH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1690585
- Former names
- Magenta Therapeutics, Inc. (until Sep 8, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | — | — | — |
| Operating income | -$177.9M | -$101.9M | -$48.2M | -$29.7M | -$74.7M |
| Net income | -$162.3M | -$85.0M | -$43.6M | -$28.5M | -$71.1M |
| Diluted EPS | -$4.20 | -$2.55 | -$8.45 | -$32.57 | -$1.29 |
| Operating cash flow | -$129.1M | -$78.2M | -$36.9M | -$29.1M | -$59.5M |
| Free cash flow | — | — | — | -$29.4M | -$60.8M |
| Total assets | $530.9M | $374.0M | $179.4M | $83.1M | $189.9M |
| Total liabilities | $37.5M | $21.5M | $10.5M | $9.5M | $17.3M |
| Stockholders' equity | $493.4M | $352.5M | $168.9M | -$44.4M | -$17.2M |
| Cash and investments | $514.4M | $357.0M | $173.7M | $69.8M | $176.9M |
| Total debt | $1.4M | $1.5M | $585,000 | $30.0M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Other events
|
Jun 12, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 22, 2026 | May 21, 2026 |
All 658 Dianthus Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.